Esophagogastric Junction Outflow Obstruction (EGJOO)

Overview

EGJOO is defined by the Chicago Classification version 4.0 (CCv4.0) as an elevated integrated relaxation pressure (IRP) in both the supine and upright positions, with ≥20% of supine swallows showing elevated intrabolus pressurization, in the presence of preserved esophageal peristalsis (Kim et al., Abdominal Radiology, 2025; Li et al., World Journal of Gastroenterology, 2022). The preserved peristalsis is what separates EGJOO from achalasia, in which peristalsis is absent (Kahrilas et al., Clinical Gastroenterology and Hepatology, 2018).

The reason EGJOO sits at the crossroads of a foregut practice — rather than in a silo — is that it is a genuinely heterogeneous entity with a long list of possible causes, only some of which are true LES disease (Patcharatrakul et al., Annals of the New York Academy of Sciences, 2020). CCv4.0 deliberately reclassified a manometric EGJOO pattern as an inconclusive diagnosis: to be considered a clinically meaningful, "conclusive" disorder, the patient must have symptoms (dysphagia and/or non-cardiac chest pain) and objective confirmation of obstruction on timed barium esophagram (TBE) or functional lumen imaging probe (FLIP) (Ahuja et al., Neurogastroenterology & Motility, 2026; DeLay et al., Clinical Gastroenterology and Hepatology, 2021). This phenotyping discipline — operating only on the confirmed obstructor and deferring the artifactual or self-limited majority — is the entire reason EGJOO must be managed by a specialist who understands esophageal physiology, not treated reflexively because a manometry report carries the label.

A substantial share of manometric EGJOO is also reflux-related or anatomic — a sliding or paraesophageal hiatal hernia, a peptic stricture, or prior fundoplication can all produce the same manometric pattern — which is why EGJOO interlinks directly with our GERD / Acid Reflux pillar, Hiatal & Paraesophageal Hernia page, and Esophageal Stricture page, in addition to the achalasia / Heller myotomy / esophageal dilation axis (Clayton, The Esophagus, 2021; DeLay et al., Neurogastroenterology & Motility, 2016).

‍

Causes

Causes are conventionally divided into functional (true LES dysfunction or an artifact/physiologic effect) and mechanical/structural (Parker and Swanstrom, The Esophagus, 2021; Kahrilas et al., Clinical Gastroenterology and Hepatology, 2018):

• Early or incompletely expressed achalasia — a subset of EGJOO, particularly with spastic or hypercontractile features in the esophageal body, represents an early achalasia variant and may progress (DeLay et al., Clinical Gastroenterology and Hepatology, 2021).

• Mechanical obstruction — hiatal hernia, peptic or other esophageal stricture, a ring, extrinsic compression, tumor or infiltrative disease, and eosinophilic esophagitis can all produce a manometric EGJOO pattern. Up to 28% of manometric EGJOO stems from structural causes rather than primary LES dysfunction (DeLay et al., Clinical Gastroenterology and Hepatology, 2021).

• Post-surgical anatomy — prior fundoplication (too tight or slipped) or other foregut surgery (Parker and Swanstrom, The Esophagus, 2021).

• Opioid-induced esophageal dysmotility — chronic opioid use impairs LES relaxation and is an increasingly recognized, reversible cause that must be queried in every patient (Gyawali et al., Gastroenterology, 2026; Kim et al., Abdominal Radiology, 2025).

• Manometric artifact / false-positive measurement — IRP elevation from catheter position, a hiatal hernia, or measurement issues, with no true obstruction (Kahrilas et al., Clinical Gastroenterology and Hepatology, 2018).

• Idiopathic (truly functional) EGJOO — when all of the above are excluded; in long-term follow-up studies, no definitive cause is identified in roughly two-thirds of cases (Liu et al., Neurogastroenterology & Motility, 2019).

‍

Risk Factors

• Chronic opioid use — a leading and reversible contributor to EGJ outflow obstruction (Gyawali et al., Gastroenterology, 2026).

• Hiatal hernia and longstanding GERD — anatomic and reflux-related drivers of a secondary EGJOO pattern (DeLay et al., Neurogastroenterology & Motility, 2016).

• Prior foregut/antireflux surgery — especially fundoplication that is too tight or has slipped (Parker and Swanstrom, The Esophagus, 2021).

• Eosinophilic esophagitis and esophagitis — inflammatory wall stiffening that mimics or causes outflow obstruction (Parker and Swanstrom, The Esophagus, 2021).

• Esophageal stricture, ring, or mass — structural narrowing at or near the EGJ (Kahrilas et al., Clinical Gastroenterology and Hepatology, 2018).

‍

How EGJOO Affects the Body

When outflow obstruction is genuine, the non-relaxing LES raises resistance to bolus passage across the EGJ; the still-contracting esophageal body must push against that resistance, producing impaired bolus clearance and retention of food and liquid in the esophagus (Sanagapalli et al., American Journal of Gastroenterology, 2021). This is reflected objectively as barium column retention on TBE (column height >5 cm at 1 minute and >2 cm at 5 minutes) and reduced EGJ distensibility on FLIP (Patel et al., Gastroenterology, 2022; DeLay et al., Clinical Gastroenterology and Hepatology, 2021). Patients experience this as the sensation of food sticking, slow transit, or chest discomfort. Crucially, when the manometric pattern is an artifact, a medication effect, or a mild/incidental finding, there is often no meaningful physiologic obstruction at all — which is precisely why objective confirmation of impaired emptying is required before the LES is irreversibly disrupted (Ahuja et al., Neurogastroenterology & Motility, 2026).

‍

Complications

Complications include persistent dysphagia, food stasis,

• Progression to achalasia in a minority — a subset of true EGJOO is an early achalasia variant, though in natural-history studies only a small proportion progress (Liu et al., Neurogastroenterology & Motility, 2019; Kahrilas et al., Clinical Gastroenterology and Hepatology, 2018).

• Dysphagia, food retention, and weight loss in cases with genuine, significant obstruction (Sanagapalli et al., American Journal of Gastroenterology, 2021).

• Harm from unnecessary intervention — the most important "complication" of EGJOO is iatrogenic: performing an irreversible, muscle-destructive LES therapy (pneumatic dilation, myotomy) on a patient whose EGJOO was an artifact, a structural problem, or self-limited, exposing them to perforation risk and post-procedure reflux for no benefit (Ahuja et al., Neurogastroenterology & Motility, 2026; Patel et al., Gastroenterology, 2022).

• Post-treatment GERD — LES-directed therapies, especially POEM, can induce significant reflux (Sarici et al., Journal of Gastrointestinal Surgery, 2023).

‍

Symptoms and Signs

Dysphagia to solids and/or liquids — the dominant symptom in symptomatic EGJOO, present in roughly three-quarters of patients in referral cohorts (Sanagapalli et al., American Journal of Gastroenterology, 2021).

Non-cardiac chest pain — a common alternative dominant symptom, after cardiac causes are excluded (Patel et al., Gastroenterology, 2022).

Regurgitation, heartburn, and the sensation of food holdup — particularly when the EGJOO is reflux- or hernia-related (DeLay et al., Neurogastroenterology & Motility, 2016).

Asymptomatic / minimally symptomatic / incidental — a large fraction of manometric EGJOO is discovered incidentally and is minimally symptomatic, and such cases can be managed expectantly (Parker and Swanstrom, The Esophagus, 2021; Kahrilas et al., Clinical Gastroenterology and Hepatology, 2018).

‍

Diagnosis

The diagnosis of a clinically meaningful EGJOO is a deliberate, multi-step process, not a single manometry report (Ahuja et al., Neurogastroenterology & Motility, 2026):

• High-resolution manometry (HRM) — establishes the pattern: elevated IRP in supine and upright positions, ≥20% of swallows with elevated intrabolus pressurization, and preserved peristalsis per CCv4.0 (Kim et al., Abdominal Radiology, 2025). Provocative maneuvers — the rapid drink challenge and solid/test swallows — markedly improve the ability to separate clinically relevant, treatment-responsive EGJOO from spontaneously remitting cases, and should be part of the protocol (Sanagapalli et al., American Journal of Gastroenterology, 2021).

• Upper endoscopy — mandatory to exclude mechanical and mucosal causes (stricture, ring, mass, hiatal hernia, eosinophilic esophagitis), with biopsies as indicated. A poorly described outside endoscopy should be repeated (Parker and Swanstrom, The Esophagus, 2021).

• Confirmatory physiologic testing — TBE and/or FLIP — required by CCv4.0 to convert an "inconclusive" manometric pattern into a "conclusive," actionable diagnosis. Barium retention on timed barium esophagram and reduced EGJ distensibility on FLIP are the objective markers of true obstruction (DeLay et al., Clinical Gastroenterology and Hepatology, 2021; Nguyen et al., AGA FLIP Clinical Practice Update, 2025). Discordance among HRM, TBE, and FLIP is common, so concordant abnormality on more than one modality increases confidence before any irreversible LES-disruptive therapy (Nguyen et al., AGA FLIP Clinical Practice Update, 2025).

• Medication and surgical history — explicit review for opioid use and prior foregut surgery, both reversible/anatomic explanations (Gyawali et al., Gastroenterology, 2026).

• Selective cross-sectional imaging — CT or endoscopic ultrasound when infiltrative disease or extrinsic compression is suspected, recognizing that routine CT/EUS has a low additional yield in otherwise unexplained EGJOO (Liu et al., Neurogastroenterology & Motility, 2019).

‍

Differential Diagnosis

• Achalasia (types I–III) — the central distinction; achalasia shows absent peristalsis, whereas EGJOO preserves it (see our Achalasia page) (Kahrilas et al., Clinical Gastroenterology and Hepatology, 2018).

• Mechanical obstruction — peptic or other stricture, ring, or tumor at/near the EGJ (see our Esophageal Stricture page) (Kim et al., Abdominal Radiology, 2025).

• Hiatal / paraesophageal hernia — a frequent anatomic cause of a secondary EGJOO pattern (see our Hiatal & Paraesophageal Hernia page) (DeLay et al., Neurogastroenterology & Motility, 2016).

• Eosinophilic esophagitis — inflammatory cause of dysphagia and wall stiffening; diagnosed by biopsy (Parker and Swanstrom, The Esophagus, 2021).

• GERD / reflux-related dysmotility — overlapping symptoms, and reflux testing with a PPI trial may be both diagnostic and therapeutic (see our GERD / Acid Reflux pillar) (Patel et al., Gastroenterology, 2022).

• Opioid-induced esophageal dysfunction — reversible with opioid reduction (Gyawali et al., Gastroenterology, 2026).

• Functional dysphagia / manometric artifact — no true obstruction on confirmatory testing (Gyawali et al., Gastroenterology, 2026).

‍

Lifestyle Modifications

Because so much of EGJOO is secondary or self-limited, conservative measures are often the whole treatment (Patel et al., Gastroenterology, 2022):

• Opioid reduction or avoidance, in partnership with the prescribing clinician, when opioids are implicated (Gyawali et al., Gastroenterology, 2026).

• Anti-reflux measures — weight management, smaller meals, avoiding late-night eating, and head-of-bed elevation — when EGJOO is reflux- or hernia-related (see our GERD / Acid Reflux pillar).

• Eating adaptations during symptomatic periods — thorough chewing, adequate fluids with meals, upright posture — to ease bolus transit.

• Observation with symptom-based follow-up for incidental or minimally symptomatic EGJOO, given the high rate of spontaneous resolution (Parker and Swanstrom, The Esophagus, 2021).

‍

Treatment Options

Treatment is entirely dependent on cause, symptom severity, and objective confirmation — and the guiding principle is conservative-first (Patel et al., Gastroenterology, 2022). A diagnosis of EGJOO does not by itself warrant therapy (Patel et al., Gastroenterology, 2022).

• Treat the underlying cause first. Reflux esophagitis is treated with intensive acid suppression; eosinophilic esophagitis with topical steroids and dilation; a secondary EGJOO from a hiatal hernia is treated by repairing the hernia; a too-tight prior fundoplication is revised; opioids are reduced (Parker and Swanstrom, The Esophagus, 2021; DeLay et al., Neurogastroenterology & Motility, 2016). See our Hiatal & Paraesophageal Hernia, GERD / Acid Reflux, and Esophageal Stricture pages.

• Expectant management for incidental, mild, or minimally symptomatic cases, given spontaneous resolution in a large share — 52%–92% of patients with mild symptoms may resolve without treatment, and conservatively managed functional EGJOO shows symptom remission in roughly 78% (Patel et al., Gastroenterology, 2022; Sanagapalli et al., American Journal of Gastroenterology, 2021).

• Conservative LES-directed therapy (first line when intervention is indicated). For confirmed, moderately-to-severely symptomatic functional EGJOO, start with endoscopic (standard) dilation (pooled response ~69.6%) and/or botulinum toxin injection to the LES (pooled response ~63.6%) — the latter also useful diagnostically and in poor surgical candidates, though botulinum toxin is used off-label for this indication (Patel et al., Gastroenterology, 2022; Parker and Swanstrom, The Esophagus, 2021). See our Esophageal Dilation page.

• For non-cardiac chest pain as the dominant symptom, smooth-muscle relaxants or neuromodulators (e.g., tricyclic antidepressants) are a reasonable initial approach (Patel et al., Gastroenterology, 2022).

• Definitive LES disruption (confirmed, refractory functional EGJOO). When conservative measures fail in objectively confirmed disease, options parallel achalasia: pneumatic dilation (response ~66.7%, perforation risk <1% for EGJOO), laparoscopic Heller myotomy with partial (Dor) fundoplication, and POEM (Parker and Swanstrom, The Esophagus, 2021; Patel et al., Gastroenterology, 2022). In a head-to-head series, Heller myotomy with Dor fundoplication and POEM were equally effective (favorable outcome 85.7% vs 82.4% at ~2 years), but POEM produced substantially more objective reflux and near-complete loss of esophageal body function, making Heller-Dor particularly attractive when preserving peristalsis and limiting post-procedure reflux matters (Sarici et al., Journal of Gastrointestinal Surgery, 2023). This is the one-to-one surgical link to our Heller Myotomy page; POEM and esophageal dilation are the secondary procedural spokes.

‍

When to See a Doctor

Any persistent difficulty swallowing, the sensation of food sticking in the chest, or recurrent non-cardiac chest pain warrants evaluation — dysphagia is never a normal symptom and always requires explanation (Patcharatrakul et al., Annals of the New York Academy of Sciences, 2020). Patients who have been handed an outside manometry report labeled "EGJOO" should seek a foregut specialist before agreeing to any LES-disrupting procedure, because the label alone is not an indication to treat (Patel et al., Gastroenterology, 2022).

‍

When to Seek Treatment

Seek prompt specialized evaluation for progressive dysphagia, significant unintentional weight loss, or food impaction, and seek urgent assessment for chest pain until a cardiac cause has been excluded (Patel et al., Gastroenterology, 2022). Because a manometric EGJOO pattern can reflect an underlying stricture, hiatal hernia, eosinophilic esophagitis, or — rarely — malignancy, the appropriate first step is a complete diagnostic workup (endoscopy plus confirmatory TBE/FLIP), not immediate intervention (Ahuja et al., Neurogastroenterology & Motility, 2026; Kim et al., Abdominal Radiology, 2025).

Long-Term Outlook

For most patients, the long-term outlook is excellent, because the great majority of EGJOO is managed conservatively and either resolves or stabilizes (Parker and Swanstrom, The Esophagus, 2021). The patients who need the most careful long-term follow-up are those with confirmed functional EGJOO who undergo LES disruption — they require monitoring for recurrence and for post-procedure reflux, which is especially relevant after POEM and is a key reason Heller myotomy with a partial fundoplication is favored in appropriate candidates (Sarici et al., Journal of Gastrointestinal Surgery, 2023). Patients with a secondary EGJOO pattern — from a hiatal hernia, reflux, eosinophilic esophagitis, or opioids — have an outlook that tracks with control of that underlying problem, which is why EGJOO is best managed within a comprehensive foregut program rather than in isolation (DeLay et al., Neurogastroenterology & Motility, 2016).

‍

Prognosis

The prognosis of EGJOO is generally favorable, largely because the manometric finding so often reflects a self-limited or secondary process rather than progressive disease (Kahrilas et al., Clinical Gastroenterology and Hepatology, 2018). A large proportion of patients improve with observation or treatment of the underlying cause, and only a minority progress to achalasia (Liu et al., Neurogastroenterology & Motility, 2019). When EGJOO is objectively confirmed and genuinely symptomatic, carefully selected patients respond well to LES-directed therapy — roughly 90% symptomatic response in provocative-testing–selected cohorts undergoing achalasia-type therapy, and 82%–86% favorable outcomes after myotomy (Sanagapalli et al., American Journal of Gastroenterology, 2021; Sarici et al., Journal of Gastrointestinal Surgery, 2023). The main threats to a good outcome are misdiagnosis and over-treatment.

‍

Why Choose Dr. de la Cruz-Muñoz

EGJOO is the most over-diagnosed major esophageal motility pattern, and the single biggest mistake in its management is treating the label on a manometry report rather than the patient in front of you. Dr. Nestor de la Cruz-Muñoz, MD, FACS, DABOM, is a board-certified minimally invasive foregut and bariatric surgeon in Miami whose practice is built around exactly this kind of careful phenotyping. Every patient referred with an EGJOO pattern is worked up systematically — repeat or high-quality endoscopy, review for opioids and prior surgery, high-resolution manometry with provocative testing, and confirmatory timed barium esophagram or FLIP — so that irreversible, muscle-destructive therapy is reserved only for those with objectively confirmed, genuinely symptomatic obstruction. Just as importantly, this practice treats EGJOO at the crossroads where it actually lives: the secondary cases driven by a hiatal hernia, reflux, eosinophilic esophagitis, or a stricture are managed by fixing the real problem (see our Hiatal & Paraesophageal Hernia, GERD / Acid Reflux, and Esophageal Stricture pages), while the confirmed functional cases are offered the full LES-directed ladder — dilation, botulinum toxin, pneumatic dilation, and, when definitive treatment is warranted, laparoscopic Heller myotomy with a partial fundoplication that relieves the obstruction while protecting against reflux (see our Heller Myotomy page). That discipline — knowing when not to operate as surely as when to — is what makes this practice a trusted regional referral destination for complex swallowing disorders across South Florida.